Here's Why Novartis (NVS) is a Strong Momentum Stock

Novartis (NVS) is highlighted as a momentum pick by Zacks despite a #3 (Hold) rank, carrying a VGM Score of A and a Momentum Style Score of B; shares are up 7.1% over the past four weeks. Zacks reports that two analysts raised fiscal 2025 EPS estimates in the last 60 days, lifting the Zacks consensus by $0.04 to $8.87 and noting an average earnings surprise of +4.6%. The firm’s growth drivers cited include products Kesimpta, Pluvicto, Scemblix, Kisqali, Leqvio and Fabhalta, and the piece reiterates prior strategic M&A/divestiture activity (Animal Health sale ~$5.4bn, influenza business $275m, Roche stake sale $20.7bn) as context for portfolio strength.

Analysis

Market structure: Novartis (NVS) benefits directly — growing revenues from Kesimpta, Leqvio (inclisiran), Pluvicto and oncology franchises widen durable cash flow and pricing power versus mid‑cap biologics. Competitors (Amgen, Pfizer, Roche peers) face share pressure in cholesterol (PCSK9/stable statin adjuncts) and MS/oncology niches; payor negotiations will determine realized pricing and uptake. Higher predictable specialty demand supports credit and narrows Novartis bond spreads; CHF inflows may strengthen FX versus cyclical USD exposure.

Risk assessment: Key tail risks are regulatory/reimbursement reversals (Medicare/CMS decisions, EU price controls), a major safety signal on any blockbuster (>-20% equity shock), or failed Phase III readouts for late‑stage assets; probability medium but impact high within 3–12 months. Short term (days–weeks) momentum can persist (7% four‑week move); medium term (quarters) EPS revisions around uptake data matter — watch consensus FY2025 EPS $8.87 and any >5% downward drift. Hidden dependency: adoption hinges on payer formularies and primary‑care willingness to prescribe inclisiran injections.

Trade implications: Core long exposure to NVS (2–3% portfolio) captures pipeline optionality and buyback/M&A optionality from Roche proceeds; use covered calls (30–45d, 5–7% OTM) to harvest premium if neutral. For directional upside, buy 12–18 month call LEAPS (limit 1% notional) to capture multi‑quarter adoption; consider pair trade long NVS vs short PFE (or another US large cap with weaker late‑stage pipeline) for 3–12 month relative alpha.

Contrarian angles: Consensus labels NVS a mere momentum/higher‑quality pharma but underweights balance‑sheet optionality from the $20.7bn Roche sale and disciplined M&A that can accelerate EPS; market may underprice buyback‑driven EPS uplift. Conversely Leqvio adoption could be overhyped — if uptake stalls (new scripts growth <5% MoM over two quarters) the stock can reprice sharply; that creates both downside stop and contrarian long entry on a >10% pullback.

Key Decisions for Investors

• Establish a 2–3% long position in NVS within 2 weeks to capture pipeline and capital allocation optionality; set a stop‑loss at -12% and plan to add to 4–5% if shares decline >8% within 30 trading days.
• Sell 30–45 day covered calls 5–7% OTM against the existing or newly initiated NVS position to generate incremental yield while keeping upside participation; roll if implied vol spikes >25% above 60‑day median.
• Buy Jan 2026 (12–18 month) OTM LEAPS calls sized to 0.8–1.0% of portfolio notional to express convex upside from Leqvio/Kesimpta adoption; trim if FY2025 consensus EPS falls >5% or if 3‑month new script growth for Leqvio <5% MoM.
• Implement a pair trade: long NVS (2%) / short PFE (1.5%) for 3–12 months to exploit superior late‑stage pipeline and buyback optionality; unwind if relative performance reverses by >7% intraperiod or if PFE issues a major buyback/M&A announcement.
• Monitor catalysts over next 90 days: CMS/Medicare reimbursement guidance for inclisiran, Q‑reports with Leqvio/Kesimpta volume trends, and any safety/regulatory headlines; if negative catalyst materializes and NVS drops >10%, consider scaling into 3–5% conviction position.